Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity—a potential diagnostic pitfall in patients with MOG-EM/MOGAD
Authors:
- S. JariusSJS. Jarius
- M. RingelsteinMRM. Ringelstein
- K. SchandaKSK. Schanda
- K. RuprechtKRK. Ruprecht
- M. Korporal-KuhnkeMKM. Korporal-Kuhnke
- A. ViehöverAVA. Viehöver
- M. W. HümmertMHM. W. Hümmert
- P. SchindlerPSP. Schindler
- V. EndmayrVEV. Endmayr
- M. GastaldiMGM. Gastaldi
- C. TrebstCTC. Trebst
- D. FranciottaDFD. Franciotta
Open Access
- 13 April 2024
- journal article
- letter
- Published by Springer Nature in Journal of Neurology
- Vol. 271 (7) , 4660-4671
Abstract
Background: Myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD) is the most important differential diagnosis of both multiple sclerosis and neuromyelitis optica spectrum disorders. A recent proposal for new diagnostic criteria for MOG-EM/MOGAD explicitly recommends the use of immunoglobulin G subclass 1 (IgG1)- or IgG crystallizable fragment (Fc) region-specific assays and allows the use of heavy-and-light-chain-(H+L) specific assays for detecting MOG-IgG. By contrast, the utility of MOG-IgG3-specific testing has not been systematically evaluated. Objective: To assess whether the use of MOG-IgG3-specific testing can improve the sensitivity of MOG-IgG testing. Methods: Re-testing of 22 patients with a definite diagnosis of MOG-EM/MOGAD and clearly positive MOG-IgG status initially but negative or equivocal results in H+L- or Fc-specific routine assays later in the disease course (i.e. patients with spontaneous or treatment-driven seroreversion). Results: In accordance with previous studies that had used MOG-IgG1-specific assays, IgG subclass-specific testing yielded a higher sensitivity than testing by non-subclass-specific assays. Using subclass-specific secondary antibodies, 26/27 supposedly seroreverted samples were still clearly positive for MOG-IgG, with MOG-IgG1 being the most frequently detected subclass (25/27 [93%] samples). However, also MOG-IgG3 was detected in 14/27 (52%) samples (from 12/22 [55%] patients). Most strikingly, MOG-IgG3 was the predominant subclass in 8/27 (30%) samples (from 7/22 [32%] patients), with no unequivocal MOG-IgG1 signal in 2 and only a very weak concomitant MOG-IgG1 signal in the other six samples. By contrast, no significant MOG-IgG3 reactivity was seen in 60 control samples (from 42 healthy individuals and 18 patients with MS). Of note, MOG-IgG3 was also detected in the only patient in our cohort previously diagnosed with MOG-IgA+/IgG– MOG-EM/MOGAD, a recently described new disease subvariant. MOG-IgA and MOG-IgM were negative in all other patients tested. Conclusions: In some patients with MOG-EM/MOGAD, MOG-IgG is either exclusively or predominantly MOG-IgG3. Thus, the use of IgG1-specific assays might only partly overcome the current limitations of MOG-IgG testing and—just like H+L- and Fcγ-specific testing—might overlook some genuinely seropositive patients. This would have potentially significant consequences for the management of patients with MOG-EM/MOGAD. Given that IgG3 chiefly detects proteins and is a strong activator of complement and other effector mechanisms, MOG-IgG3 may be involved in the immunopathogenesis of MOG-EM/MOGAD. Studies on the frequency and dynamics as well as the clinical and therapeutic significance of MOG-IgG3 seropositivity are warranted.Keywords
Funding Information
- Universitätsklinikum Heidelberg
This publication has 32 references indexed in Scilit:
- Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System DemyelinationJAMA Neurology, 2023
- Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosisJournal of Neurology, 2023
- Cell-based assays for the detection of MOG antibodies: a comparative studyJournal of Neurology, 2020
- Role of IgG3 in Infectious DiseasesTrends in Immunology, 2019
- MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und AntikörpertestungDer Nervenarzt, 2018
- Pathogenicity of human antibodies against myelin oligodendrocyte glycoproteinAnnals of Neurology, 2018
- Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter studyJournal of Neurology, 2017
- Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigenJournal of the Neurological Sciences, 2010
- Acute Disseminated EncephalomyelitisArchives of Neurology, 2005
- Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravisJournal of Neuroimmunology, 1981